Exelixis has announced the availability of Cometriq (cabozantinib), indicated for medullary thyroid cancer (MTC), in the US. Diplomat Specialty Pharmacy is distributing the product across the US. Cometriq that is developed to inhibit ...
Tags: Exelixis, Cometriq, tyrosine kinases
The USFDA has accepted Exelixis' new drug application for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer and granted priority review designation. ...
Tags: FDA, new drug application, Priority Review Designation
Exelixis has completed the submission of new drug application (NDA) for cabozantinib as a treatment for progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) patients, with the FDA. Cabozantinib is ...
Tags: submission of new drug application, FDA, pharmaceutical product